Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval
By Denny Jacob
Bristol Myers Squibb disclosed that the U.S. Food and Drug Administration granted accelerated approval of Augtyro.
The biopharmaceutical product developer said the approval is based on results from a Phase 1/2 study which evaluated Augtyro in adult patients with neurotrophic tyrosine receptor kinase positive solid tumors.
The treatment's approval applies to adult and pediatric patients ages 12 years and up with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, among other factors.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 13, 2024 17:23 ET (21:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now